Managed Care Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bavarian Nordic
Phase II trial with Imvamune in HIV infected patients initiated
August 16th, 2005
Bavarian Nordic has initiated a phase II trial to investigate the safety and immunogenicity of Imvamune in HIV infected subjects. The trial involves 150 volunteers and is being conducted at five sites in the United States. This is Bavarian Nordic's second clinical study to evaluate the safety of Imvamune in HIV infected patients and are the only studies evaluating MVA as a safe smallpox vaccine in this population of people, which are contradicted to traditional smallpox vaccines. Recently, Bavarian Nordic also completed enrollment and vaccination in a phase I clinical study with subjects suffering from atopic dermatitis, another population of people...
Source: Managed Care Business Week (2005-08-16)
|
